• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

表型源自T细胞的贴壁淋巴因子激活的杀伤细胞大量释放肿瘤坏死因子α、干扰素γ和白细胞介素-6。

High release of tumor necrosis factor alpha, interferon gamma and interleukin-6 by adherent lymphokine-activated killer cells phenotypically derived from T cells.

作者信息

Koberda J, Bergmann L, Mitrou P S, Hoelzer D

机构信息

Department of Internal Medicine, J. W. Goethe University, Frankfurt/M., Federal Republic of Germany.

出版信息

J Cancer Res Clin Oncol. 1991;117(5):425-30. doi: 10.1007/BF01612762.

DOI:10.1007/BF01612762
PMID:1909699
Abstract

Adherent lymphokine-activated killer cells (A-LAK) are highly potent cytotoxic cells, which are shown to be derived not only from natural killer (NK)/K cells but phenotypically also from T cells. The generation and phenotypical and functional characterisation of these T-cell-derived A-LAK are described. In contrast to non-adherent cells (NA-LAK) and unseparated LAK (UN-LAK), these mostly CD3+ CD56+ CD8+ cells display a high degree of expansion following initial interleukin-2 (rIL-2) activation and further culturing in autologous conditioned medium. A comparison of cytotoxic activities of cultured cells reveals a significantly higher oncolytic ability of A-LAK cells against both K562 and Daudi cells than that of cultured controls of NA-LAK and UN-LAK. In addition, A-LAK are characterised by a marked endogenous cytokine release of interferon gamma, tumour necrosis factor alpha and IL-6 as well as by their shedding of p55 IL-2 receptor after exposure to IL-2. The results demonstrate A-LAK to be the lymphocyte subpopulation with the most cytotoxic activity and endogenous cytokine release after exposure to IL-2. The improvement of techniques for long-term cultures may be of interest for future therapeutic approaches.

摘要

黏附性淋巴因子激活的杀伤细胞(A-LAK)是高效的细胞毒性细胞,已证明它们不仅来源于自然杀伤(NK)/K细胞,而且在表型上也来源于T细胞。本文描述了这些T细胞来源的A-LAK的生成以及表型和功能特征。与非黏附性细胞(NA-LAK)和未分离的LAK(UN-LAK)不同,这些主要为CD3+CD56+CD8+的细胞在初始白细胞介素-2(rIL-2)激活并在自体条件培养基中进一步培养后显示出高度的扩增。对培养细胞的细胞毒性活性进行比较发现,A-LAK细胞对K562和Daudi细胞的溶瘤能力明显高于NA-LAK和UN-LAK的培养对照。此外,A-LAK的特征在于显著内源性释放干扰素γ、肿瘤坏死因子α和IL-6,以及在暴露于IL-2后脱落p55 IL-2受体。结果表明,A-LAK是暴露于IL-2后具有最强细胞毒性活性和内源性细胞因子释放的淋巴细胞亚群。长期培养技术的改进可能对未来的治疗方法具有重要意义。

相似文献

1
High release of tumor necrosis factor alpha, interferon gamma and interleukin-6 by adherent lymphokine-activated killer cells phenotypically derived from T cells.表型源自T细胞的贴壁淋巴因子激活的杀伤细胞大量释放肿瘤坏死因子α、干扰素γ和白细胞介素-6。
J Cancer Res Clin Oncol. 1991;117(5):425-30. doi: 10.1007/BF01612762.
2
Augmented human-tumor-cytolytic activity of peripheral blood lymphocytes and cells from a mixed lymphocyte/tumor culture activated by interleukin-12 plus interleukin-2, and the phenotypic characterization of the cells in patients with advanced carcinoma.白细胞介素-12加白细胞介素-2激活的外周血淋巴细胞和混合淋巴细胞/肿瘤培养细胞的增强的人肿瘤细胞溶解活性,以及晚期癌患者细胞的表型特征。
J Cancer Res Clin Oncol. 1997;123(9):478-84. doi: 10.1007/BF01192201.
3
Interleukin-2-activated killer cell activity in colorectal tumor patients: evaluation of in vitro effects by prothymosin alpha1.结直肠癌患者中白细胞介素-2激活的杀伤细胞活性:胸腺素α1对其体外作用的评估
J Cancer Res Clin Oncol. 1997;123(8):420-8. doi: 10.1007/BF01372545.
4
Enhancement of MHC-unrestricted cytotoxic activity of human CD56+ CD3- natural killer (NK) cells and CD3+ T cells by rhamnogalacturonan: target cell specificity and activity against NK-insensitive targets.鼠李半乳糖醛酸聚糖增强人CD56+ CD3-自然杀伤(NK)细胞和CD3+ T细胞的MHC非限制性细胞毒性活性:靶细胞特异性及对NK不敏感靶标的活性
J Cancer Res Clin Oncol. 1994;120(7):383-8. doi: 10.1007/BF01240135.
5
Augmentation of murine lymphokine-activated killer cell cytotoxicity by beta-cyclodextrin-benzaldehyde.β-环糊精-苯甲醛增强小鼠淋巴因子激活的杀伤细胞的细胞毒性作用
J Cancer Res Clin Oncol. 1991;117(2):109-14. doi: 10.1007/BF01613133.
6
Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.黏附性淋巴因子激活的杀伤细胞抑制自体人正常骨髓祖细胞。
Blood. 1991 Jun 1;77(11):2389-95.
7
Mechanisms of superior anti-tumor cytotoxic response of interleukin 15-induced lymphokine-activated killer cells.白细胞介素15诱导的淋巴因子激活的杀伤细胞具有卓越抗肿瘤细胞毒性反应的机制。
J Immunother. 2005 Jan-Feb;28(1):44-52. doi: 10.1097/00002371-200501000-00006.
8
Phenotypic analysis of nylon-wool-adherent suppressor cells that inhibit the effector process of tumour cell lysis by lymphokine-activated killer cells in patients with advanced gastric carcinoma.晚期胃癌患者中抑制淋巴因子激活的杀伤细胞对肿瘤细胞溶解效应过程的尼龙毛黏附抑制细胞的表型分析。
J Cancer Res Clin Oncol. 1994;120(4):240-7. doi: 10.1007/BF01372563.
9
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
10
Involvement of MHC class I molecule and ICAM-1 in the enhancement of adhesion and cytotoxic susceptibility to immune effector cells of tumor cells transfected with the interleukin (IL)-2, IL-4 or IL-6 gene.主要组织相容性复合体I类分子和细胞间黏附分子-1在转染白细胞介素(IL)-2、IL-4或IL-6基因的肿瘤细胞增强对免疫效应细胞的黏附及细胞毒性敏感性中的作用。
J Cancer Res Clin Oncol. 1997;123(11-12):602-8. doi: 10.1007/s004320050112.

引用本文的文献

1
In vivo regulation of transforming growth factor beta 1 transcription by immunotherapy: interleukin-2 impairs interferon-alpha-stimulated increase in steady-state mRNA levels of transforming growth factor beta 1.免疫疗法对转化生长因子β1转录的体内调节:白细胞介素-2削弱干扰素-α刺激引起的转化生长因子β1稳态mRNA水平的升高。
Cancer Immunol Immunother. 1994 May;38(5):304-10. doi: 10.1007/BF01525508.
2
Development of four donor-specific phenotypes in human long-term lymphokine-activated killer cell cultures.人长期淋巴因子激活杀伤细胞培养物中四种供体特异性表型的发育。
Cancer Immunol Immunother. 1994 Nov;39(5):305-12. doi: 10.1007/BF01519983.

本文引用的文献

1
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.淋巴因子激活的杀伤细胞现象。白细胞介素2激活的自体人外周血淋巴细胞对天然杀伤抗性新鲜实体瘤细胞的杀伤作用。
J Exp Med. 1982 Jun 1;155(6):1823-41. doi: 10.1084/jem.155.6.1823.
2
Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.用淋巴因子激活的杀伤细胞(LAK)和重组白细胞介素2(RIL-2)对小鼠肝转移瘤进行过继性免疫治疗,可介导免疫原性和非免疫原性肉瘤以及一种腺癌的消退。
J Immunol. 1985 Dec;135(6):4273-80.
3
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.关于使用淋巴因子激活的杀伤细胞和白细胞介素-2或单独使用高剂量白细胞介素-2治疗157例晚期癌症患者的进展报告。
N Engl J Med. 1987 Apr 9;316(15):889-97. doi: 10.1056/NEJM198704093161501.
4
The nylon wool adherence of rat mononuclear cells: physical, chemical and biological influences.大鼠单核细胞的尼龙毛黏附:物理、化学及生物学影响
J Clin Lab Immunol. 1988 Aug;26(4):201-8.
5
A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.一种利用人贴壁淋巴因子激活的杀伤细胞产生用于过继性免疫治疗的抗肿瘤效应细胞的新方法。
Cancer Res. 1988 Jun 15;48(12):3461-9.
6
Lymphokine-activated killer cells in rats. III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells.大鼠中的淋巴因子激活的杀伤细胞。III. 一种纯化大颗粒淋巴细胞及其快速扩增并转化为淋巴因子激活的杀伤细胞的简单方法。
J Exp Med. 1988 Jan 1;167(1):15-29. doi: 10.1084/jem.167.1.15.
7
A subset of natural killer cells in peripheral blood displays a mature T cell phenotype.外周血中的一部分自然杀伤细胞表现出成熟T细胞表型。
J Exp Med. 1986 Jul 1;164(1):351-6. doi: 10.1084/jem.164.1.351.
8
Immunotherapy of cancer using interleukin 2: current status and future prospects.使用白细胞介素-2进行癌症免疫治疗:现状与未来前景
Immunol Today. 1988 Feb;9(2):58-62. doi: 10.1016/0167-5699(88)91261-3.
9
In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors.脑肿瘤患者血液中贴壁型淋巴因子激活杀伤细胞的体外生成及其抗肿瘤活性
Cancer Res. 1988 Nov 1;48(21):6069-75.
10
Lymphokine-activated killer cell activity in patients with primary and metastatic malignant liver tumors.原发性和转移性恶性肝肿瘤患者的淋巴因子激活的杀伤细胞活性
Hepatology. 1989 Aug;10(2):221-7. doi: 10.1002/hep.1840100217.